Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF

About this update from Spectral Medical Inc

[{"type":"text","content":"Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF\n\n\n\n TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) --\n \n Spectral Medical Inc.\n \n (“\n \n Spectral” or the “Company”\n \n )\n \n (TSX: EDT)\n \n , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced that it has filed a final short form base shelf prospectus (the “\n \n Base Shelf Prospectus\n \n ”) with the securities regulatory authorities in each of the provinces of Canada, except Québec (the “\n \n Securities Regulators\n \n ”) on September 26, 2025 (the “\n \n Effective Date\n \n ”).\n \n\n The Base Shelf Prospectus allows Spectral to qualify the distribution by way of a prospectus of up to $100 million of common shares, debt securities, subscription receipts, warrants and units, or any combination thereof, from time to time, during the 25-month period from the Effective Date. The specific terms of any offering under the Base Shelf Prospectus will be established in a prospectus supplement, which will be filed with the applicable Securities Regulators in connection with any such offering.\n \n\n This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.\n \n\n Spectral has also revised its Annual Information Form (“\n \n AIF\n \n ”) for the year ended December 31, 2024, as requested by the Ontario Securities Commission, to disclose a director’s prior role as an executive officer and director of a corporation which was involved in bankruptcy proceedings, and further, to incorporate updates regarding the release of topline results from the Tigris clinical trial.\n \n\n A copy of the Base Shelf Prospectus and revised AIF can be found under the Company’s profile on SEDAR+ at www.sedarplus.ca.\n \n\n\n About Spectral\n \n\n\n Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that rem...

More updates from Spectral Medical Inc